Skip to main content

Table 4 Univariate and multivariate analysis of risk factor for infectious and non-infectious pulmonary toxicity

From: Effect of dose rate on pulmonary toxicity in patients with hematolymphoid malignancies undergoing total body irradiation

  Infectious Non-infectious
SHR 95% CI P-value SHR 95% CI P-value
Univariate analysis
 Group
  Reduced dose rate group 1 (ref)    1 (ref)   
  Conventional dose rate group 1.77 0.81–3.85 0.153 4.06 0.90–18.28 0.068
 Total dose (Gy) 1.38 1.02–1.87 0.038 0.83 0.55–1.26 0.381
 Daily dose (Gy)
  Daily dose < 3 1 (ref)    1 (ref)   
  Daily dose ≥3 0.52 0.25–1.10 0.087 0.68 0.37–1.22 0.201
 Women 1.22 0.64–2.34 0.545 1.10 0.35–3.44 0.871
 Age at TBI (year) 1.00 0.98–1.02 0.854 0.99 0.96–1.02 0.486
 Cancer type
  ALL 1 (ref)    1 (ref)   
  AML 1.69 0.87–3.31 0.124 1.40 0.30–6.57 0.668
  Others 1.22 0.48–3.09 0.671 1.26 0.36–4.44 0.718
 Unrelated donor 1.30 0.68–2.48 0.436 0.98 0.34–2.85 0.971
 Conditioning regimen
  Cyclophosphamide 1 (ref)    1 (ref)   
  Cyclophosphamide + other* 1.65 0.65–4.20 0.290 Cannot be calculated Cannot be calculated 0.921
  Others 0.80 0.29–2.19 0.659 Cannot be calculated Cannot be calculated 0.925
 Prior chemotherapy regimens
  1 1 (ref)    1 (ref)   
  2 0.60 0.27–1.35 0.219 0.45 0.07–2.97 0.405
   ≥ 3 1.25 0.60–2.60 0.551 2.20 0.42–11.42 0.349
Multivariate analysis
 Group
  Reduced dose rate group 1 (ref)      
  Conventional dose rate group 2.38 1.02–5.54 0.045    
 Total dose (Gy) 1.40 1.07–1.85 0.016    
 Daily dose (Gy) 0.24 0.07–0.83 0.025    
 Cancer type
  ALL 1 (ref)      
  AML 1.69 0.83–3.42 0.146    
  Others 1.41 0.56–3.52 0.463    
  1. *other: cytarabine, fludarabine, etoposide † others: cytarabine/fludaraibine, busulfan/fludarabine/etoposide, melphalan, melphalan/fludarabine, thiotepa